Tamoxifen enhances erlotinib-induced cytotoxicity through down-regulating AKT-mediated thymidine phosphorylase expression in human non-small-cell lung cancer cells
- 1 March 2014
- journal article
- Published by Elsevier in Biochemical Pharmacology
- Vol. 88 (1) , 119-127
Abstract
No abstract availableKeywords
Funding Information
- National Science Council, Taiwan (NSC 102-2320-B-415-006, NSC 102-2314-B-002-095)
- National Taiwan University Hospital, Hsin-Chu Branch, Taiwan (HCH102-02, HCH103-013)
This publication has 41 references indexed in Scilit:
- Clinical experience with erlotinib in non-small-cell lung cancer (NSCLC)Drugs of Today, 2006
- Erlotinib in Previously Treated Non–Small-Cell Lung CancerNew England Journal of Medicine, 2005
- EGF Receptor As a Therapeutic Target: Patient Selection and Mechanisms of Resistance to Receptor-Targeted DrugsJournal of Clinical Oncology, 2003
- Tamoxifen: Is it Safe? Comparison of Activation and Detoxication Mechanisms in Rodents and in HumansCurrent Drug Metabolism, 2003
- Ligand-Induced, Receptor-Mediated Dimerization and Activation of EGF ReceptorCell, 2002
- Understanding the genotoxicity of tamoxifen?Carcinogenesis, 2001
- Epidermal Growth Factor Receptor Tyrosine Kinase as a Target for Anticancer TherapyDrugs, 2000
- Cancer statistics, 1999CA: A Cancer Journal for Clinicians, 1999
- Enhancing Effects of Epidermal Growth Factor on Human Squamous Cell Carcinoma Motility and Matrix Degradation But Not GrowthTumor Biology, 1996
- Epidermal growth factor-related peptides and their receptors in human malignanciesCritical Reviews in Oncology/Hematology, 1995